Results 1 to 10 of about 361,051 (341)
Deutsche medizinische Wochenschrift (1946), 2017 Acute myeloid leukemia (AML) has been genetically characterized extensively and can now be subdivided into 9 to 11 pathogenetically different subtypes according to their profile of driver mutations. In clinical practice karyotyping and molecular analysis of NPM1, cEBPa and FLT3-ITD are required for treatment stratification and potentially genotype ...
Souichi Adachi +4 more
core +6 more sources
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) [PDF]
Haematologica, 2008 Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin (NPMc+ acute myeloid leukemia) shows distinctive biological and clinical features.
Arcangelo Liso +22 more
doaj +5 more sources
Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers
eJHaem, 2021 Acute myeloid leukemia (AML) is associated with a high economic and clinical burden. Recently novel therapies have been added to standard treatment regimens. Here, we evaluated the economic impact of AML up until the introduction of these novel therapies.
Emma Hernlund +6 more
doaj +1 more source
Acute myeloid leukemia: update in diagnosis and treatment in Brazil [PDF]
Einstein (São Paulo), 2011 Objective: To identify how the Brazilian hematology centerstreated and diagnosed cases of acute myeloid leukemia in 2009.Methods: An epidemiological observational multicenter study of11 listed Brazilian centers that treat acute myeloid leukemia ...
Ricardo Helman +12 more
doaj +4 more sources
Apollo Medicine, 2004 AbstractAdvances in our understanding of the pathophysiology of acute myeloid leukemia (AML) have not yet led to major improvements in disease-free and overall survival of adults with this disease. Only about one-third of those between ages 18–60 who are diagnosed with AML can be cured; disease-free survival is rare and current therapy devastating in ...
Richard M, Stone +2 more
openaire +3 more sources
Haematologica, 2019 Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical benefits of differentiation therapies are negligible in acute myeloid ...
Jianbiao Zhou +13 more
doaj +1 more source
Haematologica, 2008 We investigated the NPM1 mutation status or subcellular expression of NPM protein (nuclear vs. aberrant cytoplasmic) at diagnosis and relapse in 125 patients with acute myeloid leukemia from Italy and Germany.
Brunangelo Falini +11 more
doaj +1 more source
Frontiers in Oncology, 2022 Myeloid sarcoma is a rare extramedullary tumor of immature myeloid cells. Certain known acute myeloid leukemia cytogenetic abnormalities, in particular t(8,21), has been associated with a higher incidence.
Xuemei Shu +4 more
doaj +1 more source
Uncommon CD markers in acute myeloid leukemia
Bangabandhu Sheikh Mujib Medical University Journal, 2018 This study was done to assess the unusual CD expression in 100 cases of acute myeloid leukemia from October 2016 to April 2018. The age limit was from 3 to 50 years.
Azad Abul Kalam +3 more
doaj +1 more source
Biomarkers of leukemia risk: benzene as a model. [PDF]
, 1998 Although relatively rare, leukemias place a considerable financial burden on society and cause psychologic trauma to many families. Leukemia is the most common cancer in children.
Smith, MT, Zhang, L
core +3 more sources